We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




AI Tool Performs Automatic Segmentation and Lesion Detection in Prostate MRI Scans

By MedImaging International staff writers
Posted on 14 Apr 2022
Image: New AI tool for prostate MRI analysis to support PI-RADS scoring (Photo courtesy of RSIP Vision)
Image: New AI tool for prostate MRI analysis to support PI-RADS scoring (Photo courtesy of RSIP Vision)

The Prostate Imaging–Reporting and Data System (PI-RADS) scoring method was developed to allow uniform scale for prostate cancer assessment. It consists of descriptive parameters for the lesion shape, location, intensity, and restriction, each of which corresponds to a different score representing suspicious features for prostatic cancer. Currently, it is performed manually and is a time-consuming task for radiologists, with a high rate of inter-observer variability. Now, a new tool for prostate MRI analysis performs segmentation of the prostate, its sub-sections, and lesions. It also analyzes the lesions’ intensity, restriction, size, and shape, and provides a baseline for PI-RADS score.

RSIP Vision’s (Jerusalem, Israel) new PI-RADS assistant provides objective analysis of the prostate MRI scan, with measurable statistics which can be used to improve scoring accuracy. Also, it is common to perform follow-up scans in patients diagnosed with prostatic cancer. The PI-RADS assistant compares lesions from previous scans and presents the differences to the radiologist, providing a map of the lesion growth, withering, or stability, thus reducing examination time and lowering mis-diagnosis rate. The new vendor-neutral technology will be available to third-party MRI manufacturers and viewer solutions, allowing a more accurate and efficient way to report prostate MRI examination.

“MRI is an advanced imaging tool, specifically for soft tissue like the prostate gland, with potential for improvement using AI,” said Ron Soferman, CEO at RSIP Vision. “Deep learning (DL) algorithms can be developed for accurate segmentation of the prostate, the transition zone (TZ), the peripheral zone (PZ), and the suspicious lesions. The system can automatically detect and calculate the lesions’ dimensions, volume, intensity, restriction, and edge smoothness in all the different scan parameters. Additionally, this tool can compare current and previous scans and highlight the differences, providing additional feedback for the radiologist prior to scoring.”

Related Links:
RSIP Vision 

Ultrasound-Guided Biopsy & Visualization Tools
Endoscopic Ultrasound (EUS) Guided Devices
X-Ray Generator
Advantage Plus Generators
Adjustable Mobile Barrier
M-458
Digital Radiography System (Ceiling Free)
Digix CF Series

Channels

General/Advanced Imaging

view channel
Image: A multinational study reports that AI can quickly generate clinically acceptable radiotherapy plans across care settings (Photo courtesy of Adobe Stock)

AI Tool Automates Radiotherapy Planning for Cervical and Prostate Cancer

Cervical cancer causes most of its global mortality in low- and middle-income countries, where radiotherapy capacity and specialist staff are limited. Treatment planning is labor-intensive and can delay... Read more

Imaging IT

view channel
Image: Researchers develop a vision-language model trained on large-scale data to generate clinically relevant findings from chest computed tomography images through visual question answering (Ms. Maiko Nagao from Meijo University, Japan)

Interactive AI Tool Supports Explainable Lung Nodule Assessment

Lung cancer is a leading cause of cancer mortality, and timely characterization of pulmonary nodules on chest computed tomography (CT) is essential for directing care. Interpreting nodule morphology demands... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.